Revvity Launches AI Software to Revolutionize Preclinical Imaging

Published: 30 Sep 2025

Author: Precedence Research

Share :

Revvity, Inc. has unveiled its latest innovation for life sciences researchers, the Living Image Synergy AI multimodal analysis software. This is a powerful platform for integrating and promoting imaging workflows across various preclinical modalities. This solution enables the integration of all optical information into a single environment, utilizing advanced AI-driven technology. Revvity is expected to accelerate the discovery process, enhance reproducibility, and streamline the preclinical research process for scientists worldwide by addressing long-standing issues, including fragmented analysis tools and time-consuming workflows.

The introduction of this software is a strategic move toward Revvity, which seeks to rewrite the rules of in vivo imaging analysis. Conventional imaging processes have traditionally involved researchers moving between various platforms and tools, which introduce inefficiency and inconsistent risks. Living Image Synergy AI removes such bottlenecks by consolidating analysis and adding intuitively supported AI-enhanced capabilities. This is especially important in drug discovery during its initial phase, where understanding of disease progression and drug effects either succeeds or fails in development schedules

Living Image Synergy AI also emphasizes the importance of Revvity in the subject of reproducibility, which is among the most relevant areas of contemporary biomedical research. The software enables the elimination of human variability that has historically impaired imaging outcomes by standardizing cross-modal analysis and incorporating AI-based applications, whose implementation can be used to segment and quantify components. It implies that findings in one laboratory can be more readily reproduced and confirmed in another, ultimately leading to more reliable science.

The launch in the industry highlights the growing presence of artificial intelligence in life sciences. Although AI has already revolutionized clinical imaging and diagnostics, its application in preclinical research is still in its early stages of development. The introduction of AI-based automation to in vivo imaging analysis by Revvity may establish a new standard that may be incorporated into the day-to-day operations of laboratories.